Glucose

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
måndag, januari 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
måndag, januari 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
måndag, januari 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Retrieved on: 
måndag, januari 8, 2024
SCD, LNP, Liver, Beam Therapeutics, Pfizer, Conference, Genotype, Sickle cell disease, Gene editing, Second wave, Survival, ESCAPE, Biotechnology, IND, Research, AAT, Pizzicato, Mortality, G6PC, Therapy, Third wave, Clinical trial, Glucose, DSM-IV codes, GMP, Trial of the century, AATD, Transplant, Growth, Investment, Hematology, Stem cell, HBF, Safety, Liver disease, Piz, CTA, Genetic distance, Beam

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Key Points: 
  • “Our vision is to establish Beam as a sustainable, fully integrated company pioneering a new class of genetic medicines with base editing.
  • Preclinical models suggest base editing could lead to improved HbF induction and lower residual disease-causing hemoglobin S compared to existing gene therapy options.
  • The company is on-track to report initial data on multiple patients from the BEACON trial in the second half of 2024.
  • Beam expects to report an initial clinical dataset for BEAM-201 in the second half of 2024.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
torsdag, januari 4, 2024
Coma, Urine, Hepatic encephalopathy, Ascites, Kidney, Oliguria, Physician, Benign prostatic hyperplasia, Blood volume, Uric acid, Organic acid, Anuria, Urinary retention, NYHA, Furosemide, Cerebral edema, Hypersensitivity, Diuresis, Thrombosis, Deafness, Glucose, Azotemia, Ototoxicity, Creatinine, Tinnitus, Traction, BUN, Hypoproteinemia, Edema, Growth, Investment, Congestion, Huber loss, Patient, Bruise, Dehydration, CO2, Heart failure, Cirrhosis, Embolism, History, Erythema, Pharmaceutical industry

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Retrieved on: 
tisdag, januari 2, 2024
Clutch (eggs), CGM, Diabetes, Blood, Doctor of Philosophy, MARD, Glucose, Longevity, Calibration, Medical device

The Company announces the successful completion of their first preclinical study of the implantable CBGM.

Key Points: 
  • The Company announces the successful completion of their first preclinical study of the implantable CBGM.
  • In comparison, many continuous glucose monitoring (CGM) systems measure glucose in the interstitial fluid, which lags behind blood glucose.
  • The Company also announces a second milestone: the commencement of long-term preclinical testing on the implantable CBGM.
  • GlucoTrack is committed to commercializing an implantable CBGM with a long-term sensor life, no requirement for an additional wearable component, and a once-only calibration event.

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Retrieved on: 
tisdag, januari 2, 2024
Liver, Medical Subject Headings, Marketing, Kidney, European Commission, Diabetes, INN, Risk, Allergy, ATC, Hypoglycemia, Hormone, International, Diet, Pancreas, European, Insulin, Metformin, Disease, Blood, Language, Glycated hemoglobin, DPP-4, Glucose, Type, Tablet, Select, Committee, Patient, Safety, Pioglitazone, Anatomy, Medicine, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Switch Health develops Canada’s first at-home diagnostic Diabetes test

Retrieved on: 
torsdag, november 30, 2023
Patient, Purolator, Glucose, Interview, Risk, Death, STI, Kidney, Insulin, Diabetes Canada, Diabetes, HPV, Glycated hemoglobin, Hospital, Kidney disease, DBS, A1C, CSI: Vegas, Cell, Cardiovascular disease, Medical device

Switch Health's innovative at-home HbA1c test allows people with diabetes or those suspecting the condition to collect Dry Blood Spot (DBS) samples at home.

Key Points: 
  • Switch Health's innovative at-home HbA1c test allows people with diabetes or those suspecting the condition to collect Dry Blood Spot (DBS) samples at home.
  • To get started, users can visit the Switch Health website, select the HbA1c test kit, and complete an intake form, which determines medical necessity and public coverage of test processing (currently only for Ontario residents.)
  • According to Diabetes Canada , people living with diabetes face a higher risk of hospitalization due to cardiovascular disease and end-stage renal disease.
  • This marks Switch Health's latest at-home, self-collected test, following the introduction of at-home HPV and STI testing kits this fall.

Syntron Bioresearch Product Pipeline Analysis- Pipeline Products and Ongoing Clinical Trials Overview - ResearchAndMarkets.com

Retrieved on: 
torsdag, december 28, 2023
Biotechnology, Health, Clinical Trials, Medical Devices, Urobilinogen, Allergy, Research, Anemia, Bilirubin, Blood, Cancer, Fertility, Glucose, Infection, Intelligence, Oil

The "Syntron Bioresearch Inc - Product Pipeline Analysis, 2023 Update" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Syntron Bioresearch Inc - Product Pipeline Analysis, 2023 Update" company profile has been added to ResearchAndMarkets.com's offering.
  • Syntron Bioresearch Inc (SYNTRON) is a medical device company that develops and manufactures in-vitro immunodiagnostic test systems.
  • The company provides products such as immunochromatographic assays, enzyme immunoassays, biochemical and chemical assays, microstrip readers, colorimetric assay systems, microwell strip readers, microplate readers and microplate washers.
  • This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products.

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Retrieved on: 
tisdag, november 14, 2023
Diet, Exercise, CGM, Obesity, Glucose, NHS, Conference, National Health Service, Quality of life, Pharmacotherapy, Sidoti, Weight loss, Education, Cryptocurrency, Pharmaceutical industry, Tirzepatide, Nemaura Medical

Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.

Key Points: 
  • This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.
  • Nemaura's program leverages the power of its world-first daily wear non-invasive CGM technology, allowing individuals to gain insights into how their body deals with glucose.
  • In pilot studies with the UK's National Health Service (NHS), Nemaura's program has demonstrated encouraging outcomes.
  • The incorporation of GLP-1 agonists like Ozempic, Wegovy and Mounjaro adds a powerful layer of support for individuals seeking effective and sustainable weight loss.